Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- WEN-HUI FANG, Ph. D.
Chief of Family medicine department
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tri-Service General Hospital, National Defense Medical Center, Taipei City,
Taipei, Taiwan
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Apr 2023
- Primary completion
- 31 Oct 2025
- Completion
- 31 Oct 2025
- Last update posted
- 28 Aug 2025
- Registered enrollment
- 80
- Registry id
- NCT05737342
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.